Form 4: COMPASS Pathways Director Granted 26,000 Share Options

David Y Norton, a Director of COMPASS Pathways plc, has been granted 26,000 share options with an exercise price of $4.52, vesting by June 2026.

Summary

• David Y Norton, a Director of COMPASS Pathways plc (CMPS), was granted 26,000 share options on June 12, 2025.
• The options have an exercise price of $4.52 per share.
• These options will vest in full upon the earlier of June 12, 2026, or the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026.
• The expiration date for these options is June 11, 2035.
• Following this transaction, David Norton beneficially owns 26,000 derivative securities (share options).

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is generally a positive sign of aligning management incentives with shareholder value. There are no negative operational or financial disclosures.

Positives

• The grant of share options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options have a long expiration date (June 11, 2035), providing ample time for potential value realization.

Negatives

• The document does not contain any explicitly negative information regarding the company's operations or financial health, as it is a Form 4 filing focused on insider transactions.

Risks

• The value of the granted options is subject to the future performance of COMPASS Pathways plc's stock price; if the stock price does not exceed the exercise price of $4.52, the options may not be in-the-money.
• The vesting schedule ties the full realization of the options to future dates, meaning the director must remain with the company until at least June 2026 to fully benefit.

Future Outlook

The share options granted to the director are set to vest in full by the earlier of June 12, 2026, or the date of the company's Annual General Meeting of Shareholders in 2026, indicating a future milestone for the director's equity compensation.

Management Comments

• "/s/ Meredith Prithviraj by Power of Attorney for David Norton" (Signature indicating the filing was made on behalf of David Norton).

Industry Context

This Form 4 filing reflects a routine equity compensation event for a director, common across publicly traded companies in various industries, including the biotechnology and pharmaceutical sectors where COMPASS Pathways operates. Such grants are standard practice for attracting and retaining executive talent and aligning their long-term interests with company performance.

Comparison to Industry Standards

• Granting stock options to directors is a common form of non-cash compensation across publicly traded companies, including those in the biopharmaceutical industry like COMPASS Pathways plc.
• The vesting schedule, tied to a one-year anniversary or the next AGM, is a typical structure designed to encourage continued service and long-term commitment.
• The exercise price being set at the market price on the grant date (implied by the $0 price of derivative security and the nature of a grant) is standard for incentive stock options or non-qualified stock options.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The director receives additional equity compensation, incentivizing continued service and performance.

Next Steps

• The share options will vest in full upon the earlier of June 12, 2026, or the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026.

Key Dates

Recommendation

Keywords

COMPASS Pathways, CMPS, Form 4, SEC filing, insider transaction, share options, director compensation, equity grant, beneficial ownership